These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


269 related items for PubMed ID: 27409479

  • 1. En Face Spectral-Domain Optical Coherence Tomography for the Monitoring of Lesion Area Progression in Stargardt Disease.
    Melillo P, Testa F, Rossi S, Di Iorio V, Orrico A, Auricchio A, Simonelli F.
    Invest Ophthalmol Vis Sci; 2016 Jul 01; 57(9):OCT247-52. PubMed ID: 27409479
    [Abstract] [Full Text] [Related]

  • 2. The absence of fundus abnormalities in Stargardt disease.
    Bax NM, Lambertus S, Cremers FPM, Klevering BJ, Hoyng CB.
    Graefes Arch Clin Exp Ophthalmol; 2019 Jun 01; 257(6):1147-1157. PubMed ID: 30903310
    [Abstract] [Full Text] [Related]

  • 3. Multimodal analysis of the Preferred Retinal Location and the Transition Zone in patients with Stargardt Disease.
    Verdina T, Greenstein VC, Sodi A, Tsang SH, Burke TR, Passerini I, Allikmets R, Virgili G, Cavallini GM, Rizzo S.
    Graefes Arch Clin Exp Ophthalmol; 2017 Jul 01; 255(7):1307-1317. PubMed ID: 28365912
    [Abstract] [Full Text] [Related]

  • 4. Quantifying the Rate of Ellipsoid Zone Loss in Stargardt Disease.
    Cai CX, Light JG, Handa JT.
    Am J Ophthalmol; 2018 Feb 01; 186():1-9. PubMed ID: 29126757
    [Abstract] [Full Text] [Related]

  • 5. Macular Sensitivity Measured With Microperimetry in Stargardt Disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: Report No. 7.
    Schönbach EM, Wolfson Y, Strauss RW, Ibrahim MA, Kong X, Muñoz B, Birch DG, Cideciyan AV, Hahn GA, Nittala M, Sunness JS, Sadda SR, West SK, Scholl HPN, ProgStar Study Group.
    JAMA Ophthalmol; 2017 Jul 01; 135(7):696-703. PubMed ID: 28542693
    [Abstract] [Full Text] [Related]

  • 6. Differential Disease Progression in Atrophic Age-Related Macular Degeneration and Late-Onset Stargardt Disease.
    Lindner M, Lambertus S, Mauschitz MM, Bax NM, Kersten E, Lüning A, Nadal J, Schmitz-Valckenberg S, Schmid M, Holz FG, Hoyng CB, Fleckenstein M, Foveal sparing Atrophy Study Team (FAST).
    Invest Ophthalmol Vis Sci; 2017 Feb 01; 58(2):1001-1007. PubMed ID: 28288486
    [Abstract] [Full Text] [Related]

  • 7. Macular function and morphologic features in juvenile stargardt disease: longitudinal study.
    Testa F, Melillo P, Di Iorio V, Orrico A, Attanasio M, Rossi S, Simonelli F.
    Ophthalmology; 2014 Dec 01; 121(12):2399-405. PubMed ID: 25097154
    [Abstract] [Full Text] [Related]

  • 8. Asymmetric Inter-Eye Progression in Stargardt Disease.
    Lambertus S, Bax NM, Groenewoud JM, Cremers FP, van der Wilt GJ, Klevering BJ, Theelen T, Hoyng CB.
    Invest Ophthalmol Vis Sci; 2016 Dec 01; 57(15):6824-6830. PubMed ID: 28002570
    [Abstract] [Full Text] [Related]

  • 9. Characterization of stargardt disease using polarization-sensitive optical coherence tomography and fundus autofluorescence imaging.
    Ritter M, Zotter S, Schmidt WM, Bittner RE, Deak GG, Pircher M, Sacu S, Hitzenberger CK, Schmidt-Erfurth UM, Macula Study Group Vienna.
    Invest Ophthalmol Vis Sci; 2013 Sep 27; 54(9):6416-25. PubMed ID: 23882696
    [Abstract] [Full Text] [Related]

  • 10. Early-onset stargardt disease: phenotypic and genotypic characteristics.
    Lambertus S, van Huet RA, Bax NM, Hoefsloot LH, Cremers FP, Boon CJ, Klevering BJ, Hoyng CB.
    Ophthalmology; 2015 Feb 27; 122(2):335-44. PubMed ID: 25444351
    [Abstract] [Full Text] [Related]

  • 11. The Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Studies: Design and Baseline Characteristics: ProgStar Report No. 1.
    Strauss RW, Ho A, Muñoz B, Cideciyan AV, Sahel JA, Sunness JS, Birch DG, Bernstein PS, Michaelides M, Traboulsi EI, Zrenner E, Sadda S, Ervin AM, West S, Scholl HP, Progression of Stargardt Disease Study Group.
    Ophthalmology; 2016 Apr 27; 123(4):817-28. PubMed ID: 26786511
    [Abstract] [Full Text] [Related]

  • 12. ULTRAWIDEFIELD AUTOFLUORESENCE IN ABCA4 STARGARDT DISEASE.
    Klufas MA, Tsui I, Sadda SR, Hosseini H, Schwartz SD.
    Retina; 2018 Feb 27; 38(2):403-415. PubMed ID: 28248825
    [Abstract] [Full Text] [Related]

  • 13. Vascular abnormalities in patients with Stargardt disease assessed with optical coherence tomography angiography.
    Battaglia Parodi M, Cicinelli MV, Rabiolo A, Pierro L, Bolognesi G, Bandello F.
    Br J Ophthalmol; 2017 Jun 27; 101(6):780-785. PubMed ID: 27628426
    [Abstract] [Full Text] [Related]

  • 14. ASSOCIATION BETWEEN GENOTYPE AND DISEASE PROGRESSION IN ITALIAN STARGARDT PATIENTS: A Retrospective Natural History Study.
    Di Iorio V, Orrico A, Esposito G, Melillo P, Rossi S, Sbordone S, Auricchio A, Testa F, Simonelli F.
    Retina; 2019 Jul 27; 39(7):1399-1409. PubMed ID: 29642238
    [Abstract] [Full Text] [Related]

  • 15. Quantification of peripapillary sparing and macular involvement in Stargardt disease (STGD1).
    Burke TR, Rhee DW, Smith RT, Tsang SH, Allikmets R, Chang S, Lazow MA, Hood DC, Greenstein VC.
    Invest Ophthalmol Vis Sci; 2011 Oct 10; 52(11):8006-15. PubMed ID: 21873672
    [Abstract] [Full Text] [Related]

  • 16. Impact of segmentation density on spectral domain optical coherence tomography assessment in Stargardt disease.
    Velaga SB, Nittala MG, Jenkins D, Melendez J, Ho A, Strauss RW, Scholl HP, Sadda SR.
    Graefes Arch Clin Exp Ophthalmol; 2019 Mar 10; 257(3):549-556. PubMed ID: 30613916
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 14.